Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Brian Goff Sells 11,085 Shares

Key Points

• Agios Pharmaceuticals CEO Brian Goff sold 11,085 shares at an average price of $36.67, totaling approximately $406,487, resulting in an 8.23% decrease in his ownership.
• The company's recent earnings report showed a miss in earnings per share of ($1.93), compared to the consensus estimate of ($1.74), with revenue of $12.50 million.
• Escalating interest from hedge funds has seen Erste Asset Management increase its stake in Agios Pharmaceuticals by 10.9%, adding 220,000 shares during the last quarter.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CEO Brian Goff sold 11,085 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares in the company, valued at approximately $4,529,771.76. This represents a 8.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Brian Goff also recently made the following trade(s):

• On Tuesday, June 24th, Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $33.54, for a total value of $627,198.00.

Agios Pharmaceuticals Stock Performance

AGIO traded up $0.30 during midday trading on Tuesday, reaching $35.38. 384,227 shares of the company were exchanged, compared to its average volume of 717,057. The company's fifty day moving average price is $36.29 and its 200 day moving average price is $32.68. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 3.22 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. The business had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Erste Asset Management GmbH boosted its stake in shares of Agios Pharmaceuticals by 10.9% in the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock worth $65,439,000 after buying an additional 220,000 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in Agios Pharmaceuticals during the fourth quarter valued at $49,290,000. Geode Capital Management LLC grew its holdings in Agios Pharmaceuticals by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,405,755 shares of the biopharmaceutical company's stock valued at $46,762,000 after purchasing an additional 11,174 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in Agios Pharmaceuticals by 2.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock valued at $35,152,000 after purchasing an additional 25,600 shares during the period. Finally, Deutsche Bank AG grew its holdings in Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after purchasing an additional 265,637 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Scotiabank cut their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, Bank of America decreased their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.